CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in ...

Names including Kohls, Plug Power, and Mara Holdings round out the list of the market's top 10 most-shorted stocks.

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further ...

ARK Innovation ETF (BATS: ARKK) is pushing to fresh 52-week highs Thursday, buoyed by strong performances from its key ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...

CRISPR Therapeutics (CRSP 0.79%) could revolutionize the healthcare sector, and that has made CRISPR stock a hot buy. While the company isn't profitable yet, it had its first treatment ...

Is CRISPR Therapeutics a good biotech stock to buy on the recent dip? To answer that, we need to understand what its new therapy can and can't do. What Casgevy from CRISPR Therapeutics does.

CRISPR Therapeutics stock has a market cap of $4.2 billion, which doesn't seem terribly high for a company that could be on the cusp of an approval for an expensive, life-changing treatment .

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA. Learn more on CRSP and NTLA stocks here.